dexamethasone,lenalidomide,bortezomib
takeda
['determination', 'mmsm']
phase 3 determination trial of rvd +/- asct: pfs higher (21 months) with asct, overall survival same. with 19% black patients enrolled, differences in response based on race emerged, highlighting the importance of diversity in clinical trials. #mmsm #asco22 
Multiple Myeloma Research Foundation - Accelerating the development of next generation #myeloma treatments to extend patient’s lives, and lead to a cure.